Filippi, Massimo http://orcid.org/0000-0002-5485-0479
Preziosa, Paolo
Arnold, Douglas L.
Barkhof, Frederik
Harrison, Daniel M.
Maggi, Pietro
Mainero, Caterina
Montalban, Xavier
Sechi, Elia
Weinshenker, Brian G.
Rocca, Maria A.
Article History
Received: 25 October 2022
Revised: 9 November 2022
Accepted: 10 November 2022
First Online: 24 November 2022
Declarations
:
: Massimo Filippi is Editor-in-Chief of the <i>Journal of Neurology</i>, Associate Editor of <i>Human Brain Mapping</i>, Associate Editor of <i>Radiology</i>, and Associate Editor of <i>Neurological Sciences</i>, received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational evens for Biogen, Bristol-Myers Squibb, Celgene, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme, he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA); Paolo Preziosa received speaker honoraria from Roche, Biogen, Novartis, Merck Serono, Bristol Myers Squibb and Genzyme, he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla; Douglas L. Arnold reports consulting fees from Biogen, Celgene, Frequency Therapeutics, Genentech, Merck, Novartis, Race to Erase MS, Roche, and Sanofi-Aventis, Shionogi, Xfacto Communications, grants from Immunotec and Novartis, and an equity interest in NeuroRx; Frederik Barkhof acts in steering committee or iDMC member for Biogen, Merck, Roche, EISAI and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche, Co-founder and shareholder of Queen Square Analytics LTD; Daniel M. Harrison has received consulting fees from Genentech, EMD-Serono, Biogen, and Sanofi-Genzyme, has received research support from EMD-Serono and Genentech, has received royalties and writing fees for UpToDate, Inc. and the American College of Physicians; Pietro Maggi received research support from Fund for Scientific Research (F.R.S, FNRS), Cliniques universitaires Saint-Luc Fonds de Recherche Clinique and Biogen, speaker fees from Sanofi-Genzyme and Biogen; Caterina Mainero has nothing to disclose; Xavier Montalban has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Abbvie, Actelion, Alexion, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS; Elia Sechi has nothing to disclose; Brian G. Weinshenker reports personal fees from Novartis, MedImmune/VielaBio, Horizon, Alexion, Chugai, Roche, Genentech Mitsubishi-Tanabe and UCB Biosciences, has a patent of NMO-IgG for diagnosis of neuromyelitis optica with royalties paid to RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr Volkmann und Kollegen GbR; Maria A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche and speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Merck Healthcare Germany, Merck Serono SpA, Novartis, Roche, and Teva, she receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla. She is an Associate Editor for <i>Multiple Sclerosis and Related Disorders</i>.